Argenx Builds Presence As Efgartigimod Positive In Pivotal Myasthenia Study
US BLA Submission By End Of 2020
The European biotech argenx has reported positive top-line results for its FcRn antagonist efgartigimod in generalized myasthenia gravis in the Phase III ADAPT study, and is planning to market the product itself in the US, Japan and major EU countries.
